Median anti-ADAMTS13 IgG antibody and ADAMTS13 antigen levels in patients who remained severely deficient in ADAMTS13 activity at time of caplacizumab cessation, compared with patients who showed an increase in ADAMTS13 activity >10 IU/dL
| Levels at time of stopping caplacizumab . | Severely deficient in ADAMTS13 activity (n = 18) . | Responders: ADAMTS13 activity >10 IU/dL (n = 46) . | P value . |
|---|---|---|---|
| Median anti-ADAMTS13 IgG antibody (IQR), % | 72 (32-107) | 6.5 (3.75-18) | <.0001 |
| Rising anti-ADAMTS13 IgG antibody (%) | 12/18 (67) | 3/46 (6.5) | <.0001 |
| Median ADAMTS13 antigen (IQR), % | 31 (10.75-51) | 77.5% (46.5-99) | <.0001 |
| Levels at time of stopping caplacizumab . | Severely deficient in ADAMTS13 activity (n = 18) . | Responders: ADAMTS13 activity >10 IU/dL (n = 46) . | P value . |
|---|---|---|---|
| Median anti-ADAMTS13 IgG antibody (IQR), % | 72 (32-107) | 6.5 (3.75-18) | <.0001 |
| Rising anti-ADAMTS13 IgG antibody (%) | 12/18 (67) | 3/46 (6.5) | <.0001 |
| Median ADAMTS13 antigen (IQR), % | 31 (10.75-51) | 77.5% (46.5-99) | <.0001 |